Research programme: farnesyl transferase inhibitors - Abbott Laboratories

Drug Profile

Research programme: farnesyl transferase inhibitors - Abbott Laboratories

Alternative Names: A 409100; ABT 100; Farnesyl transferase inhibitors research programme - Abbott

Latest Information Update: 23 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Class Imidazoles
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Transplant rejection

Most Recent Events

  • 20 May 2004 Preclinical trials in Transplant rejection in USA (unspecified route)
  • 20 May 2004 Data presented at the American Transplant Congress 2004 (ATC-2004) have been added to the Transplant rejection pharmacodynamics section
  • 22 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top